From Care to Cure


Mar 15, 2012

Shareholder Information Meeting 20 March 2012

In conjunction with the announcement on Friday February 17, 2012 of AMT’s Business being acquired by uniQure BV, we are pleased to invite you to our company on March 20, 2012 from 17.00 – 19.00 at AMT, 61 Meibergdreef in Amsterdam for an informational meeting on the transaction. During this meeting, Ferdinand Verdonck head of the Special Committee for the evaluation of the transaction, Jörn Aldag (CEO), Piers Morgan (CFO) Dr. Carlos Camozzi (Chief Medical Officer) will be on hand to answer investor questions. You can sign up for this meeting by sending an e-mail to amtir@amtbiopharma.com. For this meeting we have a maximum capacity of 30 people, so if you want to attend this meeting, it is necessary to register a.s.a.p. For questions or more information please contact Aicha Diba on the aforementioned e-mail or telephone +31 20 566 80 14.

Uitnodiging informatiebijeenkomst AMT – 20 maart, 2012

Naar aanleiding van de op 17 februari aangekondigde acquisitie door uniQure BV van AMT, nodigen wij u graag uit voor een informatieve bijeenkomst op 20 maart a.s. van 17.00 – 19.00 uur bij AMT aan de Meibergdreef 61 te Amsterdam. Tijdens deze bijeenkomst zullen Ferdinand Verdonck, voorzitter van het Speciale Comité , Jörn Aldag (CEO), Piers Morgan (CFO), Dr. Carlos Camozzi (Chief Medical Officer) na een korte presentatie vragen van investeerders beantwoorden. U kunt zich voor deze bijeenkomst aanmelden door een e-mail te sturen naar amtir@amtbiopharma.com. Er zijn voor deze bijeenkomst maximaal 30 plaatsen beschikbaar. Indien u bij deze meeting aanwezig wilt zijn is het dus noodzakelijk uzelf tijdig in te schrijven. Voor vragen of meer informatie kunt u contact opnemen met Aicha Diba via eerder genoemd e-mailadres of telefoonnummer 020 - 566 80 14.

Archived Press Releases
Certain statements in these press releases are “forward-looking statements” including those that refer to management’s plans and expectations for future operations, prospects and financial condition. Words such as “strategy,” “expects,” “plans,” “anticipates,” “believes,” “will,” “continues,” “estimates,” “intends,” “projects,” “goals,” “targets” and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT’s business. AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law.